|  |
| --- |
|  |
| **Figure S9**. **Combined clinical progression-free survival in patients with Malignant PEComa including all treatment episodes, regardless of line of therapy**. **A**. Kaplan-Meier curve shows clinical progression-free survival (cPFS) for patients treated with ICI, mTOR inhibitors, chemotherapy and other treatments. **B**. Kaplan-Meier curve shows cPFS in patients with TFE3 positivity as detected through either IHC or FISH compared to those that were TFE3 negative. **C**. Kaplan-Meier curve shows cPFS in patients with PEComas based on TP53 mutational status. **D**. Kaplan-Meier curve shows cPFS in patients with PEComas based on *TSC1*/*TSC2* mutational status. Log-Rank *P*-values are shown. TP53\_MUT: *TP53* mutated; TP53\_WT: *TP53* wild-type; TSC1\_MUT: *TSC1* mutated; TSC2\_MUT: *TSC2* mutated; TSC1/TSC2\_WT: *TSC1* or *TSC1* wild-type*.* TFE3\_Neg: TFE3 negative; TFE3\_Pos: TFE3 positive; NR: not reached. |